DELCATH SYSTEMS, INC.(DCTH)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,308 of 2,962 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in DCTH
Events flagged as statistical outliers against DCTH's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-16
DCTH quality score dropped 24 points (62→38) on a new filing
View source filing → - Score shock2026-08-06
DCTH quality score dropped 14 points (55→41) on a new filing
View source filing →
DCTH Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for DELCATH SYSTEMS, INC. (DCTH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DCTH at 54.7/100 on a 32-signal composite quality model, placing it at rank #1,308 of 2,962 stocks — the top half of the AI-ranked universe. DCTH scores in the top quartile across earnings quality (97.4), revenue growth (94.1). Areas of concern include revenue scale (15.0) and profitability (30.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), DELCATH SYSTEMS, INC. reports quarterly revenue of $29.1M, net income of $2.7M, free cash flow of $5.2M. Top institutional holders of DCTH by reported 13-F value include Rosalind Advisors, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. DCTH trades on the Nasdaq exchange and files with the SEC under CIK 872912. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DCTH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DELCATH SYSTEMS, INC. directly from SEC EDGAR. DELCATH SYSTEMS, INC.'s 13F Pro composite quality score has ranged between 28 and 62 since 2025, currently 54.7 — an improving long-term trajectory across 53 quarterly and live scoring snapshots.
Revenue
Q2 2026
$29.1M
Net Income
Q2 2026
$2.7M
Free Cash Flow
Q2 2026
$5.2M
ROIC
Q2 2026
7.9%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+129.1% YoYNet Income
+110.2% YoYOperating Income
+105.3% YoYEPS (Diluted)
+107.5% YoYTotal Assets
+61.4% YoYTotal Debt
Op. Cash Flow
+220.5% YoYFree Cash Flow
+209.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $85.2M +129.1% | $37.2M +1701.7% | $2.1M -24.1% | $2.7M -23.5% | $3.6M | — |
| Net Income | $2.7M +110.2% | $-26.4M +44.7% | $-47.7M -30.6% | $-36.5M -42.3% | $-25.6M -6.2% | $-24.2M |
| Operating Income | $660.0K +105.3% | $-12.4M +67.5% | $-38.2M -12.8% | $-33.9M -38.0% | $-24.5M -15.2% | $-21.3M |
| EPS (Diluted) | $0.07 +107.5% | $-0.93 +68.4% | $-2.94 +28.6% | $-4.12 -14.8% | $-3.59 +57.0% | $-8.35 |
| Total Assets | $123.6M +61.4% | $76.6M +98.4% | $38.6M +116.2% | $17.9M -46.1% | $33.1M -4.4% | $34.6M |
| Total Debt | — | $0.00 -100.0% | $10.2M -35.3% | $15.7M | — | — |
| Operating Cash Flow | $22.5M +220.5% | $-18.7M +40.2% | $-31.3M -25.3% | $-24.9M -10.4% | $-22.6M +1.2% | $-22.9M |
| Free Cash Flow | $21.0M +209.0% | $-19.2M +38.5% | $-31.3M -24.4% | $-25.2M -10.6% | $-22.7M +3.8% | $-23.6M |
Get alerted when DCTH's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for DELCATH SYSTEMS, INC. including:
Top Institutional Holders of DCTH
Rosalind Advisors, Inc.
$41.6M3,300,389 shBlackRock, Inc.
$34.1M2,706,802 shVANGUARD CAPITAL MANAGEMENT LLC
$15.4M1,221,247 shPropel Bio Management, LLC
$11.0M871,460 shGEODE CAPITAL MANAGEMENT, LLC
$9.2M733,115 shSTATE STREET CORP
$8.6M679,280 shALGERT GLOBAL LLC
$7.3M580,708 shMILLENNIUM MANAGEMENT LLC
$7.1M566,371 shDivisadero Street Capital Management, LP
$6.3M499,796 shMORGAN STANLEY
$5.1M407,983 sh
| Fund | Value | Shares |
|---|---|---|
| Rosalind Advisors, Inc. | $41.6M | 3,300,389 |
| BlackRock, Inc. | $34.1M | 2,706,802 |
| VANGUARD CAPITAL MANAGEMENT LLC | $15.4M | 1,221,247 |
| Propel Bio Management, LLC | $11.0M | 871,460 |
| GEODE CAPITAL MANAGEMENT, LLC | $9.2M | 733,115 |
| STATE STREET CORP | $8.6M | 679,280 |
| ALGERT GLOBAL LLC | $7.3M | 580,708 |
| MILLENNIUM MANAGEMENT LLC | $7.1M | 566,371 |
| Divisadero Street Capital Management, LP | $6.3M | 499,796 |
| MORGAN STANLEY | $5.1M | 407,983 |
Companies Similar to DCTH
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Xeris Biopharma Holdings, Inc.
ABEONA THERAPEUTICS INC.
Verastem, Inc.
Journey Medical Corp
Ovid Therapeutics Inc.
HARROW, INC.
ZEVRA THERAPEUTICS, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put DCTH on your watchlist
Track score changes the day DELCATH SYSTEMS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is DCTH a good stock to buy?
13F Pro's AI-powered analysis of DELCATH SYSTEMS, INC. (DCTH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DCTH are available on the DCTH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. DCTH is classified as a small company.
Which hedge funds own DCTH?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DCTH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of DELCATH SYSTEMS, INC.'s investment landscape.